Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.74 |
| ▸ | RARB | P10826 | 3/20 | 0.70 |
| ▸ | THRA | P10827 | 1/20 | 0.67 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.67 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.67 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383674 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| SCHEMBL7278960 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| SCHEMBL9325995 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| SCHEMBL14672324 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| SCHEMBL9779326 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| SCHEMBL7283625 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| SCHEMBL7281514 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| SCHEMBL7271669 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBTHRA | |
| Hydrochloric Acid SCHEMBL8541196 | 0.98 | TP53 (0.74) | TP53TSHRPLA2G4BRARBTHRA | |
| Hydrochloric Acid SCHEMBL8302098 | 0.98 | TP53 (0.74) | TP53TSHRPLA2G4BRARBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9052863-A | — | — | None | — | — | JP | disclosed |
| EP-2766450-B1 | SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS | FRAUNHOFER GES FORSCHUNG (DE) | 2018-12-12 | — | — | EP | disclosed |
| WO-2016201283-A1 | ANTIFUNGAL AGENTS | CIDARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-9273247-B2 | Substituted amino alcohols as chiral dopants | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2016-03-01 | — | — | US | disclosed |
| EP-2766450-A1 | SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. (DE) | 2014-08-20 | — | — | EP | disclosed |
| US-20140228591-A1 | SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2014-08-14 | — | — | US | disclosed |
| WO-2013053752-A1 | SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2013-04-18 | — | — | WO | disclosed |
| CN-100360512-C | Biphenylmethyl-thiazolidinediones and analogues thereof and their use as PPAR-gamma activators | GALDERMA RES & DEV (FR) | 2008-01-09 | — | — | CN | disclosed |
| US-7294639-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| JP-H0952863-A | PRODUCTION OF ALKOXYNAPHTHALENECARBOXYLIC ACID DERIVATIVE | MITSUI TOATSU CHEM INC | 1997-02-25 | — | — | JP | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0462531-B1 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0729974-A1 | Cyclic polypeptide with antibiotic activity and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| CN-1059729-A | Novel polypeptide compound and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-03-25 | — | — | CN | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-5072021-A | Liquid crystals | MITSUI TOATSU CHEMICALS, INC. (JP) | 1991-12-10 | — | — | US | disclosed |
| JP-H00952863-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | PPARG, PPARA, PPARD | TP53 384/4885TSHR 184/4885PLA2G4B 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.